External evidence supports RAAS-targeting strategies in related cardiorenal populations [5,23-25], including randomized trials of non-steroidal MR antagonism in diabetic CKD (FIDELIO-DKD, FIGARO-DKD) [24,25]; however, our cross-sectional analysis does not provide interventional or prognostic confirmation. This evidence concerns the gene NR3C2 and chronic kidney disease.